Catalyst Wire Dossier Catalyst Wire Dossier

Elahere

mirvetuximab soravtansine · ImmunoGen, Inc.
Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for Elahere, covering 2022-11-14 to 2026-03-25. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression [Phase 2]

See pricing